由诊断、医院和高技能专业的增长所驱动, 印度保健部门在Q2 FY26的交易额超过10 000英镑。 India's healthcare sector saw over ₹10,000 crore in deals in Q2 FY26, driven by growth in diagnostics, hospitals, and high-acuity specialties.

在诊断和医院的强劲增长驱动下,印度保健部门在Q2 FY26期间的交易额超过10,000卢比,诊断公司报告收入增加10-22%,医院每张占用床位的收入增加10-16%。 India's healthcare sector recorded over Rs 10,000 crore in deals during Q2 FY26, driven by strong growth in diagnostics and hospitals, with diagnostics firms reporting 10–22% revenue gains and hospitals seeing 10–16% increases in revenue per occupied bed. 诸如肿瘤学和心脏病学等高级专业的投资激增,主要链条规划了18 000多张新床位。 Investment surged in high-acuity specialties like oncology and cardiology, with major chains planning over 18,000 new beds. EBITDA高幅度为25-35%,反映了运营效率,而AI、基因组学和预防护理迅速扩大。 High EBITDA margins of 25–35% reflected operational efficiency, while AI, genomics, and preventive care expanded rapidly. 尽管存在短期差值压力,但保险覆盖面的提高、有利的人口统计以及投资者的持续兴趣都支持长期增长。 Despite near-term margin pressures, long-term growth is supported by rising insurance coverage, favorable demographics, and sustained investor interest.